Literature DB >> 25054465

Multidisciplinary management of pediatric intracranial ependymoma.

David B Mansur1.   

Abstract

Pediatric intracranial ependymoma is a rare disease representing approximately 7% of brain tumors in children aged 15 years or younger. Due to the relative rarity of these tumors, a clear standard therapy has been difficult to establish. The mainstay of treatment is surgical resection and the majority of data demonstrate improved outcome with gross total resection. The standard of care also includes postoperative radiation therapy for most patients with grade II and III tumors. Chemotherapy has been used in many capacities in this disease; however, its optimal role is yet to be defined. Current controversies such as treatment with surgery alone in completely resected tumors, use of chemotherapy for subtotally resected tumors and use of adjuvant postradiation chemotherapy are incorporated into the design of the current Children's Oncology Group clinical trial.

Entities:  

Mesh:

Year:  2013        PMID: 25054465      PMCID: PMC6166531          DOI: 10.2217/cns.13.13

Source DB:  PubMed          Journal:  CNS Oncol        ISSN: 2045-0907


  68 in total

1.  Post-operative radiation improves survival in children younger than 3 years with intracranial ependymoma.

Authors:  Matthew Koshy; Shayna Rich; Thomas E Merchant; Usama Mahmood; William F Regine; Young Kwok
Journal:  J Neurooncol       Date:  2011-06-03       Impact factor: 4.130

2.  Is gross-total resection sufficient treatment for posterior fossa ependymomas?

Authors:  Leland Rogers; Jeanette Pueschel; Robert Spetzler; William Shapiro; Stephen Coons; Terry Thomas; Burton Speiser
Journal:  J Neurosurg       Date:  2005-04       Impact factor: 5.115

3.  Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology.

Authors:  J Grill; M C Le Deley; D Gambarelli; M A Raquin; D Couanet; A Pierre-Kahn; J L Habrand; F Doz; D Frappaz; J C Gentet; C Edan; P Chastagner; C Kalifa
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

4.  Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients.

Authors:  Philippe Metellus; Jacques Guyotat; Olivier Chinot; Anne Durand; Marylin Barrie; Roch Giorgi; Anne Jouvet; Dominique Figarella-Branger
Journal:  Neuro Oncol       Date:  2010-05-19       Impact factor: 12.300

5.  Postoperative radiation therapy for grade II and III intracranial ependymoma.

Authors:  David B Mansur; Arie Perry; Veena Rajaram; Jeff M Michalski; T S Park; Jeffrey R Leonard; Lori Luchtman-Jones; Keith M Rich; Perry W Grigsby; Mary Ann Lockett; Sasha H Wahab; Joseph R Simpson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-02-01       Impact factor: 7.038

Review 6.  Prognostic factors in infants and very young children with intracranial ependymomas.

Authors:  P K Duffner; J P Krischer; R A Sanford; M E Horowitz; P C Burger; M E Cohen; H S Friedman; L E Kun
Journal:  Pediatr Neurosurg       Date:  1998-04       Impact factor: 1.162

7.  Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.

Authors:  Hendrik Witt; Stephen C Mack; Marina Ryzhova; Sebastian Bender; Martin Sill; Ruth Isserlin; Axel Benner; Thomas Hielscher; Till Milde; Marc Remke; David T W Jones; Paul A Northcott; Livia Garzia; Kelsey C Bertrand; Andrea Wittmann; Yuan Yao; Stephen S Roberts; Luca Massimi; Tim Van Meter; William A Weiss; Nalin Gupta; Wiesia Grajkowska; Boleslaw Lach; Yoon-Jae Cho; Andreas von Deimling; Andreas E Kulozik; Olaf Witt; Gary D Bader; Cynthia E Hawkins; Uri Tabori; Abhijit Guha; James T Rutka; Peter Lichter; Andrey Korshunov; Michael D Taylor; Stefan M Pfister
Journal:  Cancer Cell       Date:  2011-08-16       Impact factor: 31.743

8.  A prognostic gene expression signature in infratentorial ependymoma.

Authors:  Khalida Wani; Terri S Armstrong; Elizabeth Vera-Bolanos; Aditya Raghunathan; David Ellison; Richard Gilbertson; Brian Vaillant; Stewart Goldman; Roger J Packer; Maryam Fouladi; Ian Pollack; Tom Mikkelsen; Michael Prados; Antonio Omuro; Riccardo Soffietti; Alicia Ledoux; Charmaine Wilson; Lihong Long; Mark R Gilbert; Ken Aldape
Journal:  Acta Neuropathol       Date:  2012-02-10       Impact factor: 17.088

9.  Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study.

Authors:  Maura Massimino; Lorenza Gandola; Felice Giangaspero; Alessandro Sandri; Pinuccia Valagussa; Giorgio Perilongo; Maria Luisa Garrè; Umberto Ricardi; Marco Forni; Lorenzo Genitori; Giovanni Scarzello; Filippo Spreafico; Salvina Barra; Maurizio Mascarin; Bianca Pollo; Martina Gardiman; Armando Cama; Pierina Navarria; Maurizio Brisigotti; Paola Collini; Rita Balter; Paola Fidani; Maurizio Stefanelli; Roberta Burnelli; Paolo Potepan; Marta Podda; Guido Sotti; Enrico Madon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-04-01       Impact factor: 7.038

10.  Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons.

Authors:  Shannon M MacDonald; Sairos Safai; Alexei Trofimov; John Wolfgang; Barbara Fullerton; Beow Y Yeap; Thomas Bortfeld; Nancy J Tarbell; Torunn Yock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-03-05       Impact factor: 7.038

View more
  1 in total

Review 1.  Citation analysis of the most influential ependymoma research articles illustrates improved knowledge of the molecular biology of ependymoma.

Authors:  Nolan J Brown; Bayard Wilson; Brian V Lien; Alexander Himstead; Ali R Tafreshi; Shane Shahrestani; Jack Birkenbeuel; Katelynn Tran; David Horton; Anushka Paladugu; Lydia R Kirillova; Chen Yi Yang; Seth C Ransom; Ronald Sahyouni; Isaac Yang
Journal:  Neurosurg Rev       Date:  2021-10-06       Impact factor: 3.042

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.